With hospitals at risk, Mass. eyes lifeline for broke insurer covering 460K public employees
Amid fears of 'serious financial consequences,' Massachusetts is working to create a lifeline for a Massachusetts agency that oversees health insurance for 460,000 public employees, retirees and their dependents after it could not continue to pay providers.
In January, state Group Insurance Commission (GIC) Executive Director Matthew Veno had flagged the agency's budget shortfalls as a concern.
'This is the largest variance that we've seen in at least a decade, and this is consistent across all of our plans, and is driven primarily by rising provider prices and a couple of other topics,' he said at the time. 'We don't know where this is going to head. My concern is that it is a persistent and steady trend going forward.'
Then in April, Veno said rising provider prices and increased utilization of prescription benefits, including for GLP-1 weight loss drugs, had caused the commission to run an average $20 million monthly deficit this fiscal year.
Massachusetts Health & Hospital Association (MHA) said it was 'unacceptable' for the insurance agency to have a lack of backup options and claims the disruption in payments 'will undoubtedly result in serious financial consequences.'
Read more: Mass. health insurance companies directed to limit growth of deductibles, copays
Mercy Medical Center in Springfield said it 'is not in a financial position to absorb budget shortfalls of the state Massachusetts Group Insurance Commission.'
'While we appreciate the financial situation of the GIC, we join them in advocating for funding to resolve its budget deficiency that will not further exacerbate the financial condition of healthcare providers,' the statement continued.
But the Massachusetts Legislature didn't act before GIC officially ran out of money on Monday. All claims have remained pending since then.
The commission had been counting on a $237 million appropriation request before the Legislature.
The appropriation was the largest single request in a $756 million short-term spending bill Gov. Maura Healey filed in early April.
However, in an email sent to providers earlier this month, the GIC warned that it 'does not know how soon the legislature will pass the bill and when the GIC will receive the requested funds.'
The claims will remain pending until GIC receives the additional funds or until July 1.
This week, Massachusetts began moving forward on the requested funds.
The House advanced a $240 supplemental budget for the agency on Monday. And the Senate passed it on Thursday.
'Ensuring that the hundreds of thousands of public employees and their loved ones have access to health insurance is one of our most important responsibilities,' said Senate President Karen E. Spilka, D-Middlesex/Norfolk.
Now it is set for Healey's desk.
'The GIC is grateful to the House and Senate for passing the Governor's supplemental budget request. We look forward to lifting the hold on claims payments and promptly resuming payment of pended claims following the Governor's signature of the legislation,' GIC said in a statement to MassLive. 'We appreciate the patience of plans and providers as we worked toward resolution in a way that would minimally impact our members.'
But this isn't unique to GIC.
'The Group Insurance Commission is facing a challenge that is not unique to any insurer, as pharmaceutical usage is going up and the costs of drugs are rising at an unsustainable rate,' said Senator Cindy F. Friedman, D-4th Middlesex, the Senate's chair of the Legislature's Joint Committee on Health Care Financing.
'The Senate is actively working on measures to address this larger issue, as well as other cost drivers throughout the health care system, to relieve the pressure on insurers and the premiums that residents in the Commonwealth face,' the Arlington lawmaker continued. 'As we work towards the end goal of stabilizing health care costs, this supplemental funding for the GIC will ensure that our state employees stay covered and healthy.'
Mass. health insurance companies directed to limit growth of deductibles, copays
'Unacceptable': Health insurer for 460K Mass. public workers goes broke without backup plan
Insurance program for 460,000 Mass. residents runs out of money Monday
Read the original article on MassLive.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
19 minutes ago
- CNBC
Telehealth firm Ro enlists Serena Williams as ambassador for weight-loss drugs
Telehealth company Ro has enlisted former tennis player Serena Williams as a celebrity patient ambassador for its weight-loss treatments, it said on Thursday. She will star in a national marketing campaign for GLP-1s medication and inspire others to take the support they need to reach their health goals, a company spokesperson said. Williams, who has won 23 grand slam titles, is speaking out for the first time about using GLP-1 weight-loss treatment to improve her health and help reach her weight goals after having children, Ro said. Her grand slams make Williams the most successful female tennis player in the modern era. She won the Australian Open in 2017 while she was pregnant. The company, which sells Eli Lilly's Zepbound and Novo Nordisk's Wegovy through its weight-loss program, said Williams' husband and co-founder of social media site Reddit, Alexis Ohanian, is an investor in Ro and serves on its board.
Yahoo
21 minutes ago
- Yahoo
SERENA WILLIAMS JOINS RO AS GLP-1 CELEBRITY AMBASSADOR
The tennis icon partners with Ro to talk openly about weight, health, and the role of GLP-1 treatment NEW YORK, Aug. 21, 2025 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced that Serena Williams—23-time Grand Slam champion, four-time Olympic gold medalist, and one of the most decorated athletes in history—has been using Ro to lose weight and is joining as a celebrity patient ambassador. Williams and Ro will lead a multi-year campaign to normalize the use of GLP-1 medications for weight loss and support others on their health journeys. As part of the campaign, Williams is speaking out for the first time about using GLP-1 treatment to improve her health and help reach her weight goals after having kids. As a world-class athlete, entrepreneur, and mother, she's no stranger to discipline and resilience. But when Williams' body changed postpartum, and more time in the gym and healthy eating wasn't helping her achieve those goals, she realized she needed additional support. Williams turned to Ro to access GLP-1 treatment, high-quality clinical care, and ongoing support. "I trained at the highest level, ate a clean diet, pushed myself, and still, after having kids, my body just wouldn't respond. I realized it wasn't about willpower; it was biological. My body needed the GLP-1 and clinical support," said Williams. "I'm partnering with Ro because if I needed help as a top athlete doing everything at level 10, I know others are struggling too, and everyone deserves access to the treatment they need. This isn't a shortcut. It's healthcare." Williams' and Ro's partnership will focus on continuing to normalize, and promote open conversations around the role GLP-1s play in helping people manage their weight and take control of their health. Williams is starring in a national marketing campaign spanning digital, broadcast, and out-of-home that highlights her story and how Ro helps members like Williams achieve their health goals. "By opening up about her own health, Serena is opening doors for millions of people who have felt shamed for needing support to lose weight," said Zach Reitano, co-founder and CEO of Ro. "She's redefining what it means to be strong, once again, by setting the example that strength can also mean seeking and using medication to take control of your health. We're proud to be Serena's care partner, and even prouder to stand with her as she inspires people nationwide to reach their health goals." This announcement builds on Ro's mission to fight for patients and expand access to GLP-1 treatment through online doctor visits, personalized treatment plans, insurance coordination, education, and ongoing support. Weight management is also preventative healthcare. It follows Ro's announcement in April of NBA legend Charles Barkley joining as their first GLP-1 celebrity patient ambassador. Together, these partnerships represent Ro's commitment to reducing barriers, expanding education, and reimagining what healthcare looks like for millions of Americans. To learn more about Ro's weight loss offering, visit Disclosure: Williams' husband is an investor in Ro and serves on its board. About Ro Ro is a direct-to-patient healthcare company with a mission of helping patients achieve their health goals by delivering the easiest, most effective care possible. Ro is the only company to offer nationwide telehealth, labs, and pharmacy services. This is enabled by Ro's vertically integrated platform that helps patients achieve their goals through a convenient, end-to-end healthcare experience spanning from diagnosis, to delivery of medication, to ongoing care. Since 2017, Ro has helped millions of patients in nearly every single county in the United States, including 99% of primary care deserts. Visit for more information. Contact: press@ View original content to download multimedia: SOURCE Ro Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Altasciences Chosen by Steel Therapeutics to Support the Launch of Pivotal Toxicology Study for Fizurex™
LAVAL, Québec--(BUSINESS WIRE)-- Altasciences is pleased to have been chosen by Steel Therapeutics, Inc. ('Steel'), to initiate a pivotal toxicology study for Fizurex™, a novel topical therapy for the treatment of anal fissures. The GLP-compliant study is currently being conducted at Altasciences' preclinical facility in Columbia, MO. It marks a key milestone in Steel's regulatory development, as the company prepares for an Investigational New Drug (IND) application in early 2026. The GLP-compliant study is currently being conducted at Altasciences' preclinical facility in Columbia, MO. It marks a key milestone in Steel's regulatory development, as the company prepares for an Investigational New Drug (IND) application in early 2026. 'We're proud to be supporting Steel Therapeutics at this key stage of their development journey,' said Steve Mason, Co-COO at Altasciences. 'Our teams are aligned in their commitment to accelerate the delivery of patient-centered therapies. The initiation of this study is another example of how early collaboration and scientific rigor can bring important treatments closer to market.' Fizurex™, a patent-pending compounded wipe, has seen widespread use in clinical practice and is now progressing through the formal regulatory pathway to reach broader patient populations under FDA oversight. Steel engaged Altasciences due to their deep expertise in preclinical safety evaluation and proven ability to execute with speed and precision. 'Working with Altasciences allows us to maintain the highest standards of quality as we move Fizurex™ into its next phase of development,' said Matt Stahl, CEO and Founder of Steel Therapeutics. 'This study represents a major step forward for our company and for the patients who stand to benefit from more consistent, scalable access to this treatment.' Altasciences' integrated, collaborative approach to drug development enables companies like Steel to move efficiently from discovery through to clinical trials, all under one organizational umbrella. 'We look forward to continuing our partnership with Steel Therapeutics as they advance their portfolio of innovative, patient-focused therapies,' added Mason. About Altasciences Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences' integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, research support, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit Steel Therapeutics' mission is to improve the lives of patients by scaling access to compounded drugs that have a proven track record of safety and effectiveness. With a team of pharmacist-founders who have built and operated retail compounding programs, Steel is well-positioned to identify both high-impact drug candidates and innovative delivery systems. Steel has selected a novel treatment for anal fissures as its product entry point. The company's Fizurex™ wipe utilizes a combination therapy that is commonly compounded by pharmacists and incorporates it into a single-use wipe. By bringing rigorous safety and efficacy testing, Current Good Manufacturing Practices (CGMP), and a patient-friendly format to this drug combination, Steel believes it can dramatically improve outcomes for patients.
